Universal DX has concluded its Series B funding round. The amount raised was not disclosed, but noted investors involved include Quest Diagnostics and newcomers such as Olympus Innovation Ventures.
The funds will be used to continue the clinical trial of UDX's colorectal cancer screening blood test, Signal-C. The company initiated patient enrollment in January 2024 and aims to obtain premarket approval from the US FDA for Signal-C. UDX anticipates recruiting at least 15,000 participants across 100 sites for the Signal-C trial.
Analyst QuickTake: Prior to this, in November 2023, Universal DX raised USD 70 million in a Series B funding round , with participation from genetic testing company Quest Diagnostics, which was expected to be exclusively offering UDX's Signal-C colorectal cancer screening test in the US via a strategic partnership between the two firms.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.